The Cancer Pain Market is expected to register a CAGR of 5.9% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The growth in cancer pain is attributed to the increasing prevalence of cancer, aging populations, and improvements in the cancer treatment approach. This report gives an in-depth perspective on the dynamics of the market, its size, segmentation, and competitive landscape. The drivers of the market include the increased demand for efficient pain management solutions and the introduction of new therapies.
Purpose of the ReportThe report Cancer Pain Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Cancer Pain Market Segmentation
Drug Type- Opioids
- Non-Opioids
- Nerve blockers
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
Strategic Insights
Cancer Pain Market Growth Drivers- Growing Prevalence of Cancer: The cancer pain market is rapidly increasing globally due to several driving factors. Most probably, the most contributing factor is the growing prevalence of the disease, primarily resulting from the aging population of almost every country.
- Demand for Effective Pain Management: The more patients affected by cancer, the greater the resultant need for effective solutions in pain management. In terms of the growing awareness of the benefits of improved cancer treatments and diagnosis, there is an enhanced need for pain management during and after treatment. Because growth in the market is driven by increased awareness about the importance of pain management and a wider therapeutic range, there is an increase in demand for a better quality of life. Added to this, growing interest in the quality of life for patients with cancer and rising medical costs worldwide create favorable conditions for increasing the market for cancer pain.
- Advancements in Pain Management Therapies: Innovations in drug formulations, including extended-release opioids, non-opioid analgesics, and transdermal patches, are driving the adoption of cancer pain treatments.
- Growing Awareness About Cancer Pain Management: Awareness campaigns by healthcare organizations and governments have improved recognition of the importance of managing cancer-related pain.
- Patient-centric Treatments: Tailored treatment plans by the clinical requirements of individual patients represent one of personalized medicine. This would develop precisely targeted and effective pain management techniques. Besides, advancements in drug delivery systems, such as implantable pumps, and focused drug delivery will also provide significant improvements in pain control with fewer side effects.
- Coverage of Digital Health: The final emerging trend is the convergence of digital health technologies wearables and telemedicine that will help monitor patient symptomatology and response to treatment, thereby enabling management from a distance.
- Multimodal Pain Therapy: The growing trend to multimodal pain therapy at every stage would ensure even more optimal relief. According to the research studies, the novelty that is going to emerge in the future would be drugs related to new therapeutic and innovative concepts to deal with the confusing aspect of cancer pain.
- Develop Effective Therapies: The incidence of cancers and patient numbers are growing alarmingly, in need of more effective therapies for pain management. This creates an immense market demand. These innovative therapeutic agents, targeted therapies and immunotherapies truly hold great promise for the unmet needs of cancer pain management.
- Development in drug delivery systems: Drug delivery innovations such as oral formulations, topical formulations, and injectable formulations, would enhance compliance in treating patients. The growing interest in patient-centered care and quality-of-life-related concerns opens up exciting avenues for the development of multifaceted programs in pain management, integrating pharmacological and non-pharmacological interventions. Having extensive availability, digital health technologies will enable monitoring of patients in a remote manner, provide patient-specific treatment plans, and access care in the most underserved regions. Thus, proper resolution of the tough issues of cancer pain will create monumental opportunities for health service providers, pharmaceutical firms, and manufacturers of medical appliances.
- Development of Non-Opioid Analgesics: Increased focus on non-opioid pain relief solutions, such as cannabinoids, nerve block therapies, and targeted biologics, presents opportunities to address concerns over opioid addiction and side effects.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Cancer Pain Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Cancer Pain Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The leading players of the market are: Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grunenthal Pharma GmbH & Co. KG,, Hisamitsu Pharmaceutical Co., Inc., Insys Therapeutics, Inc., Mundipharma International Limited, Orexo AB Pfizer Inc., Teva Pharmaceutical Industries Limited
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
Personalized medicine is gaining importance with the trend of tailoring treatment according to individual patient needs. Innovative drug delivery systems are expected to improve pain control while reducing side effects. Digital health technologies are integrating to monitor patient symptoms, track treatment response, and facilitate remote pain management. Multimodal pain management, including pharmacological and non-pharmacological interventions, is becoming increasingly prevalent. With advancing research, novel therapeutic agents and innovative approaches are expected to continue the quest toward addressing the complex challenge of cancer pain.
Cancer Pain Market is expected to grow at a CAGR of 5.9% between 2023-2031
Principal drivers of the cancer pain market are, thus, several. Among them are the facts of rising cancer prevalence among age populations. The improved techniques of cancer treatment and diagnosis increase the rates of survival but have also increased the need for effective pain management. In addition, greater awareness of pain control as well as an escalation in overall healthcare spending around the world drive growth in the market. Other trends and developments that are creating new opportunities in the cancer pain market include novel therapeutic agents, innovative drug delivery systems, and the involvement of digital health technologies.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cancer Pain Market - By Drug Type
1.3.2 Cancer Pain Market - By Disease Indication
1.3.3 Cancer Pain Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CANCER PAIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CANCER PAIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CANCER PAIN MARKET - GLOBAL MARKET ANALYSIS
6.1. CANCER PAIN - GLOBAL MARKET OVERVIEW
6.2. CANCER PAIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CANCER PAIN MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. OPIOIDS
7.3.1. Overview
7.3.2. Opioids Market Forecast and Analysis
7.4. NON-OPIOIDS
7.4.1. Overview
7.4.2. Non-Opioids Market Forecast and Analysis
7.5. NERVE BLOCKERS
7.5.1. Overview
7.5.2. Nerve blockers Market Forecast and Analysis
8. CANCER PAIN MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. COLORECTAL CANCER
8.4.1. Overview
8.4.2. Colorectal Cancer Market Forecast and Analysis
8.5. BREAST CANCER
8.5.1. Overview
8.5.2. Breast Cancer Market Forecast and Analysis
8.6. PROSTATE CANCER
8.6.1. Overview
8.6.2. Prostate Cancer Market Forecast and Analysis
8.7. BLOOD CANCER
8.7.1. Overview
8.7.2. Blood Cancer Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. CANCER PAIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Cancer Pain Market Overview
9.1.2 North America Cancer Pain Market Forecasts and Analysis
9.1.3 North America Cancer Pain Market Forecasts and Analysis - By Drug Type
9.1.4 North America Cancer Pain Market Forecasts and Analysis - By Disease Indication
9.1.5 North America Cancer Pain Market Forecasts and Analysis - By Countries
9.1.5.1 United States Cancer Pain Market
9.1.5.1.1 United States Cancer Pain Market by Drug Type
9.1.5.1.2 United States Cancer Pain Market by Disease Indication
9.1.5.2 Canada Cancer Pain Market
9.1.5.2.1 Canada Cancer Pain Market by Drug Type
9.1.5.2.2 Canada Cancer Pain Market by Disease Indication
9.1.5.3 Mexico Cancer Pain Market
9.1.5.3.1 Mexico Cancer Pain Market by Drug Type
9.1.5.3.2 Mexico Cancer Pain Market by Disease Indication
9.2. EUROPE
9.2.1 Europe Cancer Pain Market Overview
9.2.2 Europe Cancer Pain Market Forecasts and Analysis
9.2.3 Europe Cancer Pain Market Forecasts and Analysis - By Drug Type
9.2.4 Europe Cancer Pain Market Forecasts and Analysis - By Disease Indication
9.2.5 Europe Cancer Pain Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Cancer Pain Market
9.2.5.1.1 Germany Cancer Pain Market by Drug Type
9.2.5.1.2 Germany Cancer Pain Market by Disease Indication
9.2.5.2 France Cancer Pain Market
9.2.5.2.1 France Cancer Pain Market by Drug Type
9.2.5.2.2 France Cancer Pain Market by Disease Indication
9.2.5.3 Italy Cancer Pain Market
9.2.5.3.1 Italy Cancer Pain Market by Drug Type
9.2.5.3.2 Italy Cancer Pain Market by Disease Indication
9.2.5.4 Spain Cancer Pain Market
9.2.5.4.1 Spain Cancer Pain Market by Drug Type
9.2.5.4.2 Spain Cancer Pain Market by Disease Indication
9.2.5.5 United Kingdom Cancer Pain Market
9.2.5.5.1 United Kingdom Cancer Pain Market by Drug Type
9.2.5.5.2 United Kingdom Cancer Pain Market by Disease Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Cancer Pain Market Overview
9.3.2 Asia-Pacific Cancer Pain Market Forecasts and Analysis
9.3.3 Asia-Pacific Cancer Pain Market Forecasts and Analysis - By Drug Type
9.3.4 Asia-Pacific Cancer Pain Market Forecasts and Analysis - By Disease Indication
9.3.5 Asia-Pacific Cancer Pain Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Cancer Pain Market
9.3.5.1.1 Australia Cancer Pain Market by Drug Type
9.3.5.1.2 Australia Cancer Pain Market by Disease Indication
9.3.5.2 China Cancer Pain Market
9.3.5.2.1 China Cancer Pain Market by Drug Type
9.3.5.2.2 China Cancer Pain Market by Disease Indication
9.3.5.3 India Cancer Pain Market
9.3.5.3.1 India Cancer Pain Market by Drug Type
9.3.5.3.2 India Cancer Pain Market by Disease Indication
9.3.5.4 Japan Cancer Pain Market
9.3.5.4.1 Japan Cancer Pain Market by Drug Type
9.3.5.4.2 Japan Cancer Pain Market by Disease Indication
9.3.5.5 South Korea Cancer Pain Market
9.3.5.5.1 South Korea Cancer Pain Market by Drug Type
9.3.5.5.2 South Korea Cancer Pain Market by Disease Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Cancer Pain Market Overview
9.4.2 Middle East and Africa Cancer Pain Market Forecasts and Analysis
9.4.3 Middle East and Africa Cancer Pain Market Forecasts and Analysis - By Drug Type
9.4.4 Middle East and Africa Cancer Pain Market Forecasts and Analysis - By Disease Indication
9.4.5 Middle East and Africa Cancer Pain Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Cancer Pain Market
9.4.5.1.1 South Africa Cancer Pain Market by Drug Type
9.4.5.1.2 South Africa Cancer Pain Market by Disease Indication
9.4.5.2 Saudi Arabia Cancer Pain Market
9.4.5.2.1 Saudi Arabia Cancer Pain Market by Drug Type
9.4.5.2.2 Saudi Arabia Cancer Pain Market by Disease Indication
9.4.5.3 U.A.E Cancer Pain Market
9.4.5.3.1 U.A.E Cancer Pain Market by Drug Type
9.4.5.3.2 U.A.E Cancer Pain Market by Disease Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Cancer Pain Market Overview
9.5.2 South and Central America Cancer Pain Market Forecasts and Analysis
9.5.3 South and Central America Cancer Pain Market Forecasts and Analysis - By Drug Type
9.5.4 South and Central America Cancer Pain Market Forecasts and Analysis - By Disease Indication
9.5.5 South and Central America Cancer Pain Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Cancer Pain Market
9.5.5.1.1 Brazil Cancer Pain Market by Drug Type
9.5.5.1.2 Brazil Cancer Pain Market by Disease Indication
9.5.5.2 Argentina Cancer Pain Market
9.5.5.2.1 Argentina Cancer Pain Market by Drug Type
9.5.5.2.2 Argentina Cancer Pain Market by Disease Indication
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CANCER PAIN MARKET, KEY COMPANY PROFILES
11.1. AOXING PHARMACEUTICAL COMPANY, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BIODELIVERY SCIENCES INTERNATIONAL, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. DAIICHI SANKYO CO., LTD.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GRUNENTHAL PHARMA GMBH AND CO. KG,
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. HISAMITSU PHARMACEUTICAL CO., INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. INSYS THERAPEUTICS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MUNDIPHARMA INTERNATIONAL LIMITED
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. OREXO AB
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Aoxing Pharmaceutical Company, Inc.
2. BioDelivery Sciences International, Inc.
3. Daiichi Sankyo Co., Ltd.
4. Grunenthal Pharma GmbH & Co. KG,
5. Hisamitsu Pharmaceutical Co., Inc.
6. Insys Therapeutics, Inc.
7. Mundipharma International Limited
8. Orexo AB
9. Pfizer Inc.
10. Teva Pharmaceutical Industries Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For